Italy's CDs submit law on abortion pill
Christian Democrat members of the Italian parliament have submittedproposed legislation that would permit pharmacists to refuse sales of the abortion pill mifepristone (often referred to as RU-486), according to Agency France Presse, which noted that the pill was banned in Italy until late last year. However, it is now available on a doctor's prescription and costs 20,000 lire ($8.88).
The contention of the CDs is that pharmacists have a right to "conscientious objection" to the pill. The proposal will be supported by the Catholic pharmacists' lobby, and Catholic Church officials have condemned use of the pill, noting that it is a "chemical abortion."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze